XIAP is an apoptotic suppressor which has E3 ubiquitin-protein ligase activity. XIAP mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1, inhibit caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B. Defects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2). XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.

Store at -20°C. If intended for use within a month, may keep at 4°C. Minimize freeze-thaw cycles.

12 months from the date of shipment when stored properly.